top of page

Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline

Writer: nuaxia
nuaxia
1 hour ago
2 min read

Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.


Johnson & Johnson announced on 16 November 2026 that it had entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront plus up to approximately $1.125 billion in contingent regulatory and commercial milestones, securing access to OLN324, an investigational Phase III bispecific antibody being developed for retinal vascular diseases including wet age-related macular degeneration and diabetic macular oedema.


Under a separate arrangement, Blackstone Life Sciences is expected to contribute $750 million over multiple years towards Phase III development after the acquisition closes, with completion anticipated before the end of 2026 subject to customary conditions; the development financing is distinct from the acquisition consideration, and the full potential transaction value is not guaranteed.

Field

Content

Article Type

Deals

Acquirer

Johnson & Johnson

Target Company

Ollin Biosciences

Deal Type

Definitive acquisition agreement

Announcement Date

16 November 2026

Transaction Status

Agreed; closing pending

Upfront Acquisition Consideration

$2.2 billion

Potential Contingent Milestones

Up to approximately $1.125 billion

Maximum Potential Acquisition Consideration

Approximately $3.325 billion

Rounded Headline Transaction Value

Up to approximately $3.3 billion

Milestone Categories

Regulatory and commercial

Milestone Payment Status

Contingent on future achievements

Principal Acquired Programme

OLN324

OLN324 Development Stage

Phase III

OLN324 Drug Modality

Bispecific antibody

Therapeutic Area

Ophthalmology

Disease Focus One

Neovascular age-related macular degeneration

Disease Focus Two

Diabetic macular oedema

Related Disease Category

Retinal vascular diseases

Separate Financing Partner

Blackstone Life Sciences

Separate Development Funding

$750 million

Development Funding Purpose

Phase III clinical development

Development Funding Timing

Over multiple years after acquisition closing

Financing Included in Acquisition Consideration

No

Expected Closing

Before the end of 2026

Closing Conditions

Subject to customary conditions

Acquisition Completed

Not at announcement

OLN324 Regulatory Approval

Not reported

What Happened

Johnson & Johnson agreed to acquire Ollin Biosciences and its late-stage ophthalmology programme.

Why It Matters

The transaction expands Johnson & Johnson's retinal disease pipeline with a late-stage investigational bispecific antibody.

Strategic Significance

Combines acquisition-led pipeline expansion with external development risk-sharing financing.

Financial Significance

The agreement includes substantial upfront consideration and additional performance-dependent milestone payments.

Financial Clarification

Blackstone's separate $750 million development funding is not part of the Ollin acquisition purchase price.

Regulatory Clarification

OLN324 remains investigational and the acquisition does not represent a medicine approval.

Key Takeaway

Johnson & Johnson plans to acquire Ollin for up to approximately $3.3 billion, with separate Blackstone funding supporting OLN324 development.

What to Watch

Transaction closing, Phase III clinical progress, regulatory milestones, development funding deployment and future ophthalmology pipeline updates.

Primary Source

Johnson & Johnson

Primary Source URL

https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ollin-biosciences-and-late-stage-bispecific-antibody-with-best-in-class-potential-in-ophthalmology

Submitted Source

Reuters

Submitted Source URL

https://www.reuters.com/legal/transactional/jj-strikes-22-billion-buyout-deal-eye-disease-biotech-ollin-biosciences-2026-11-16/

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page